Medicine Grand Rounds: Features and Outcomes of Methamphetamine Associated Pulmonary Arterial Hypertension

When:
November 8, 2017 @ 8:00 am – 9:00 am
2017-11-08T08:00:00-08:00
2017-11-08T09:00:00-08:00
Where:
LKSC, Berg Hall
Li Ka Shing Building
291 Campus Drive, Palo Alto, CA 94305
USA
Cost:
Free
Contact:
Jody Joseph
Medicine Grand Rounds: Features and Outcomes of Methamphetamine Associated Pulmonary Arterial Hypertension @ LKSC, Berg Hall | Palo Alto | California | United States

Presenters: Vinicio A. de Jesus Perez, MD and Roham Zamanian, MD
Perez: Assistant Professor of Medicine, Pulmonary and Critical Care
Zamanian: Associate Professor of Medicine, Pulmonary and Critical Care                                 Stanford University

Perez received his MD from the University of Puerto Rico Medical School and completed an internal medicine residency at Massachusetts General Hospital. He completed a fellowship in pulmonary and critical care medicine in Denver, followed by postdoctoral research training at Stanford University. He focused on researching genetic and molecular mechanisms of pulmonary hypertension (PH) and idiopathic pulmonary fibrosis (IPF) and has devoted his clinical practice to diagnosis and management of these conditions. He is presently assistant professor of medicine and staff physician of the Stanford Adult PH Clinic where he trains fellows pursuing careers in PH and IPF. He is principal investigator of a research program with the ultimate goal of identifying new therapeutic targets to treat PH and IPF.

As a medical professional belonging to a minority group, Dr. de Jesus Perez is involved in academic endeavors seeking to improve access of care for patients with disadvantageous ethnic backgrounds and promote diversity in medicine.

Zamanian specializes in the treatment of pulmonary hypertension, right heart failure, and pulmonary embolism. He has more than 13 years of sub-specialty experience in pulmonary vascular diseases. Dr. Zamanian is considered one of the leading national experts in clinical trials and drug development for pulmonary hypertension.